capsaicin + flupirtine

**Capsaicin + flupirtine** is an investigational or off-label combination of two small-molecule drugs with analgesic properties, studied primarily for their potential synergistic effects in the treatment of pain, including experimentally induced hyperalgesia in humans. Capsaicin is a selective agonist of the transient receptor potential vanilloid 1 (TRPV1) receptor, leading to desensitization of nociceptive neurons and subsequent analgesia, typically administered topically for neuropathic and musculoskeletal pain. Flupirtine is a non-opioid, non-NSAID analgesic that acts as a selective neuronal potassium channel (Kv7) opener and NMDA receptor antagonist, reducing neuronal excitability and calcium influx, and modulating pain signaling centrally[1][4][3][5][2]. The combination has been studied in experimental settings where capsaicin is used to induce hyperalgesia and flupirtine to modulate pain response, but no evidence was found for a commercially available fixed-dose combination product or approval for any indication.